<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="65149"><Indications><Indication>Schizophrenia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 2 receptor antagonist</Action><Action>CDKN1A gene modulator</Action><Action>Dopamine D1 receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action><Action>Dopamine D3 receptor antagonist</Action><Action>Dopamine D4 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Intramuscular formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company><Company>Eli Lilly &amp; Co</Company><Company>Janssen Pharmaceutica NV</Company></CompaniesSponsor><DateChangeLast>2017-02-06T00:00:00Z</DateChangeLast><DateStart>2007-10-15T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>olanzapine alone</Intervention><Intervention>quetiapine IR alone</Intervention><Intervention>risperidone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>75</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser> This was &lt;b&gt;a randomized, flexible-dose, rater-blind, parallel-group, quasi-naturalistic trial comparing the efficacy, safety, and tolerability of quetiapine , risperidone , and olanzapine in patients with schizophrenia hospitalized for severe psychotic symptoms&lt;/b&gt; [ 1075803 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A randomized, flexible-dose, rater-blind, parallel-group, quasi-naturalistic trial comparing the efficacy, safety, and tolerability of quetiapine, risperidone, and olanzapine in patients with schizophrenia hospitalized for severe psychotic symptoms</TitleDisplay><PrimaryCompletionDate></PrimaryCompletionDate><NumberOfSites>0</NumberOfSites></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>